European Medicines Agency issues summary of opinion for recommending the granting of a conditional marketing authorisation for bosutinib

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product bosutinib (Bosulif) 100 mg and 500 mg film-coated tablets intended for the treatment of chronic myelogenous leukaemia (CML). Read more here.